Dysregulated adipokine metabolism in chronic obstructive pulmonary disease

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 983-991

  Breyer, Marie Kathrin ^a,b,c   Rutten, Erica P A ^b   Locantore, Nicholas W ^d   Watkins, Michael L ^d   Miller, Bruce E ^d   Wouters, Emiel F M ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre of Expertise for Chronic Organ Failure (CIRO)   (Netherlands)

^c OTTO WAGNER HOSPITAL   (Austria)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adipokines; Gender; Inflammation; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LEPTIN;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFLAMMATION; LABORATORY DIAGNOSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; SEROLOGY; SEX DIFFERENCE; SMOKING;

ADIPOKINES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX FACTORS;

EID: 84865172175     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02686.x     Document Type: Article

References (49)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
2. Wouters EF. COPD: from an organ- to a disease-oriented approach. Copd 2008;5:73-4.
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
4. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67.
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
6. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53.
7. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5.
8. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-11.
9. Wouters EF. COPD: a chronic and overlooked pulmonary disease. Lancet 2007;370:715-6.
10. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-24.
11. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.
12. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-6.
13. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
14. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9, quiz 920.
15. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
16. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 2003;546:45-50.
17. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246:409-18.
18. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
19. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
20. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27:2300-9.
21. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
22. Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007;132:135-40.
23. Schols AM, Creutzberg EC, Buurman WA, Campfield LA, Saris WH, Wouters EF. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1220-6.
24. Breyer MK, Rutten EP, Vernooy JH, Spruit MA, Dentener MA, van der Kallen C et al. Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin. Respir Med 2011;105:1046-53.
25. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-73.
26. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
27. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
28. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006;173:79-83.
29. Dey DK, Bosaeus I, Lissner L, Steen B. Body composition estimated by bioelectrical impedance in the Swedish elderly. Development of population-based prediction equation and reference values of fat-free mass and body fat for 70- and 75-y olds. Eur J Clin Nutr 2003;57:909-16.
30. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
31. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2010;14:1193-200.
32. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-9.
33. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-23.
34. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
35. Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, Yamamoto T et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 2008;47:485-91.
36. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140:331-42.
37. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
38. Vassilakopoulos T, Zakynthinos S, Roussos C. Strenuous resistive breathing induces proinflammatory cytokines and stimulates the HPA axis in humans. Am J Physiol 1999;4 Pt 2:R1013-9.
39. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000;15:915-21.
40. Breyer MK, Spruit MA, Celis AP, Rutten EP, Janssen PP, Wouters EF. Highly elevated C-reactive protein levels in obese patients with COPD: a fat chance? Clin Nutr 2009;28:642-7.
41. van den Borst B, Gosker HR, Wesseling G, de Jager W, Hellwig VA, Snepvangers FJ et al. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. Am J Clin Nutr 2011;94:1504-12.
42. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004;109:2181-5.
43. Marques-Vidal P, Bochud M, Paccaud F, Mooser V, Waeber G, Vollenweider P. Distribution of plasma levels of adiponectin and leptin in an adult Caucasian population. Clin Endocrinol (Oxf) 2010;72:38-46.
44. Caldefie-Chezet F, Poulin A, Tridon A, Sion B, Vasson MP. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 2001;69:414-8.
45. Mercken EM, Hageman GJ, Schols AM, Akkermans MA, Bast A, Wouters EF. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:994-1001.
46. Gomez-Ambrosi J, Salvador J, Paramo JA, Orbe J, de Irala J, Diez-Caballero A et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002;35:315-20.
47. Mertens I, Considine RV, van der Planken M, Van Gaal LF. Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur J Endocrinol 2006;155:477-84.
48. Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999;30:328-37.
49. Soderberg S, Olsson T, Eliasson M, Johnson O, Ahren B. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999;245:533-43.